Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
20 nov 2007 - 13:35
Statutaire naam
Crucell N.V.
Titel
Crucell Announces PER.C6® Licensing Agreement with Acambis
Bericht
Leiden, The Netherlands, November 20, 2007– Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Acambis plc (London Stock Exchange: ACM) today announced the signing of a research license agreement for PER.C6®. The license agreement allows Acambis to use Crucell’s PER.C6® technology for an undisclosed vaccine candidate. Financial details of the agreement were not disclosed.
Gerelateerde downloads
Datum laatste update: 19 december 2025